Trial reportAIDS (London, England)2009
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
Trial report in AIDS (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Association of vitamin D with HIV infected individuals, TB infected individuals, and HIV-TB co-infected individuals: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz.BMC research notes · 2012Trial
- Bone health across the lifespan in African populations affected by HIV.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Optimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials.EClinicalMedicine · 2025Article
- Breaking Down Bone Disease in People Living with HIV: Pathophysiology, Diagnosis, and Treatment.Advances in experimental medicine and biology · 2025Review
- Bone Disease in HIV: Need for Early Diagnosis and Prevention.Life (Basel, Switzerland) · 2024Review
- Bone Health in People Living with HIV/AIDS: An Update of Where We Are and Potential Future Strategies.Microorganisms · 2023Review
- Osteoporosis and HIV Infection.Calcified tissue international · 2022Review
- Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in thepre- and post-HAART eras.Clinical rheumatology · 2020Review
- People living with HIV and fracture risk.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Review
- Use of Bisphosphonates, Calcium and Vitamin D for Bone Demineralization in Patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials.Journal of bone metabolism · 2020Article
- The Hidden Burden of Fractures in People Living With HIV.JBMR plus · 2018Review
- Continued Interest and Controversy: Vitamin D in HIV.Current HIV/AIDS reports · 2018Review
- HIV and Bone Complications: Understudied Populations and New Management Strategies.Current HIV/AIDS reports · 2016Review
- Perspectives on menopause and women with HIV.International journal of women's health · 2016Review
- Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss.Nature communications · 2015Article
- Adverse bone health among children and adolescents growing up with HIV.Journal of virus eradication · 2015Review
- Recommendations for evaluation and management of bone disease in HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- HIV infection and osteoporosis.BoneKEy reports · 2015Review
- Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.Endocrine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo evaluate the efficacy of a single dose of intravenous zoledronate for the treatment of HIV-associated osteopenia and osteoporosis.
designA double-blinded, randomized, placebo-controlled, 12-month trial of 5 mg intravenous zoledronate dose to treat 30 HIV-infected men and women with osteopenia and osteoporosis.
methodsFollowing zoledronate or placebo infusions, participants were followed for 12 months on daily calcium and vitamin D supplements. Lumbar spine and hip bone density was assessed at baseline, 6 and 12 months. Biomarkers of bone metabolism were measured at baseline, 2 weeks, 3, 6, 9, and 12 months. Student's t-test and repeated measure analyses were used to evaluate bone density and bone marker changes over time.
resultsIn the 30 HIV-infected individuals [men (27) and women (3)] in the trial, median T-scores at entry were -1.7 for the lumbar spine and -1.4 for the hip. Median CD4 cell count was 461 cells/microl, 93% had HIV-RNA viral loads less than 400 copies/ml, and 97% were taking antiretroviral medications. Bone density measured either absolutely or as sex-adjusted T-scores significantly improved in zoledronate recipients as compared with minimal changes in those receiving placebo. Bone resorption markers significantly decreased over the study period in the zoledronate recipients as compared with placebo controls. No acute infusion reactions were detected, but one patient developed uveitis, a recognized complication of zoledronate, which responded to therapy.
conclusionIn this small study, annual zoledronate appears to be a well tolerated and effective therapy for HIV-associated bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.